New gene therapy could restore sight in progressive blindness
NCT ID NCT04278131
First seen Jan 24, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This early-stage trial tests a gene therapy called BS01 for people with retinitis pigmentosa, a condition that causes gradual vision loss. The treatment uses a harmless virus to deliver a light-sensitive protein to cells in the eye, aiming to help them detect light again. About 20 adults with very limited vision will be enrolled to check safety and whether it improves light, motion, or object detection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
New Jersey Retina
RECRUITINGTeaneck, New Jersey, 07666, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.